WNC 0901
Alternative Names: WNC-0901Latest Information Update: 31 Aug 2026
At a glance
- Originator Waynola Biopharm
- Class Antineoplastics; Radiosensitisers
- Mechanism of Action DNA-activated protein kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioblastoma; Lung cancer
Most Recent Events
- 17 Apr 2026 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 22 Oct 2025 Pharmacodynamics data from a preclinical trial in Solid tummours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025 2025)
- 05 Apr 2024 Preclinical trials in Glioblastoma in Canada (PO) prior to April 2024